Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Aortic Stenosis Symptomatic Clear all
Recruiting No phase listed Observational

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

NCT05489705
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
Mavacamten, Non-mavacamten symptomatic oHCM therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
60
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial

NCT00530894
View directory record Official record
Conditions
Critical Aortic Stenosis
Interventions
Edwards SAPIEN Transcatheter Heart Valve, Surgical Valve Replacement, medical management and/or balloon aortic valvuloplasty
Device · Other
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
1,057 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT05556343
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
MYK-224
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Enrolling by invitation Not applicable Interventional

ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

NCT05932615
View directory record Official record
Conditions
Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Interventions
Navitor Transcatheter Aortic Valve Implantation (TAVI) System, Any Commercially Available Transcatheter Aortic Valve (CAV) System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
74
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle

NCT00001960
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Pacemaker therapy
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Early Feasibility Study (EFS) of Abbott's Balloon-expandable (BE) TAVI System for the Treatment of Severe, Symptomatic Aortic Stenosis

NCT07116551
View directory record Official record
Conditions
Symptomatic Severe Aortic Stenosis
Interventions
Abbott BE TAVI System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
4
States / cities
Wichita, Kansas • Minneapolis, Minnesota • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Not applicable Interventional

Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy

NCT06775886
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
Interventions
myPACE+ algorithm
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Not applicable Interventional

Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study

NCT05712161
View directory record Official record
Conditions
Aortic Stenosis, Symptomatic Aortic Stenosis, Severe Aortic Valve Stenosis, Aortic Valve Calcification
Interventions
DurAVRTM THV System
Device
Lead sponsor
Anteris Technologies Ltd.
Industry
Eligibility
65 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
5
States / cities
Tucson, Arizona • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT03470545
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
mavacamten, Placebo
Drug
Lead sponsor
MyoKardia, Inc.
Industry
Eligibility
18 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
29
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting No phase listed Observational

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

NCT06372457
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
Approved Hypertrophic Cardiomyopathy drug treatments, Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

NCT04349072
View directory record Official record
Conditions
HOCM, Hypertrophic Obstructive Cardiomyopathy
Interventions
Mavacamten, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

NCT05767346
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
28
States / cities
Anchorage, Alaska • Phoenix, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional Results available

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - PII B

NCT02184442
View directory record Official record
Conditions
Severe, Symptomatic, Calcific Aortic Stenosis
Interventions
TAVR Implantation with SAPIEN XT, TAVR Implantation with SAPIEN
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
19 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
53
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 17, 2026, 4:08 AM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

NCT04848506
View directory record Official record
Conditions
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten (5 - 20 mg)
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
52
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER

NCT03496168
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Scottsdale, Arizona • New Haven, Connecticut • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

Pirfenidone to Treat Hypertrophic Cardiomyopathy

NCT00011076
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Pirfenidone
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy

NCT06481891
View directory record Official record
Conditions
Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
33
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement

NCT01675440
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
43
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

NCT04634240
View directory record Official record
Conditions
Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis
Interventions
Percutaneous Coronary Intervention (PCI)
Procedure
Lead sponsor
University of British Columbia
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
55
States / cities
Huntsville, Alabama • Phoenix, Arizona • Palo Alto, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Not applicable Interventional Results available

SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial

NCT04722250
View directory record Official record
Conditions
Symptomatic Aortic Stenosis, Aortic Valve Stenosis, Aortic Valve Replacement
Interventions
Medtronic Evolut PRO, Evolut PRO+ or Evolut FX (where commercially available) TAV Systems, Edwards SAPIEN 3 or SAPIEN 3 Ultra THV Systems
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
1,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
61
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

STAR Trial (Siegel Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis)

NCT07278310
View directory record Official record
Conditions
Symptomatic Severe Native Aortic Stenosis, Aortic Stenosis
Interventions
TAVR Device, Siegel TAVR Device
Device
Lead sponsor
MiRus
Industry
Eligibility
18 Years and older
Enrollment
1,025 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Not applicable Interventional

Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study

NCT06680427
View directory record Official record
Conditions
Aortic Stenosis Symptomatic
Interventions
Siegel Transcatheter Aortic Valve (TAVR)
Device
Lead sponsor
MiRus
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

NCT05582395
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Mavacamten, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

NCT05186818
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
48
States / cities
Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 17, 2026, 4:08 AM EDT